The search for new anti-cancer agents therapies and treatment modalities is continuously requiring the development and availability of valuable in vivo tumor models, including, among others, orthotopic models. These, based on an orthotopic tumor implantation as opposed to heterotopic inoculation, permit accurate expression of the biological tumor nature in terms of growth rate, morphology and metastasis, thereby mimicking the disease progress for an accurate assessment of response to anti-cancer therapies.
We are offering the following orthotopic tumor-bearing syngeneic mouse models to perform in vivo efficacy evaluation, which can be built by ex vivo capabilities for biomarkers analysis and immune response characterization.
GBM model characteristics
Apart from the advantage of the tumor cells (stably expressing the 2nd generation firefly luciferase) which are intracranially implanted by stereotactic surgery, our syngeneic GBM model mimics the major human disease features including immune cell activation and infiltration, and astrogliosis, among other characteristics, and therefore allows for testing drug candidates for their ability to enhance or restore the anti-tumor immune response, in a functionally immunocompetent system.
GL261 glioma tumor-bearing model is characterized by tumor-infiltrating microglial. Immunohistochemistry processing associated with H&E staining highlights the presence of tumor-surrounding (A&B) and tumor-infiltrating (B&C) Iba1-positive microglial cells.